Madaiah Revana, MD
Interventional Cardiology · Humble, TXNPI 1013997360
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Johnson & Johnson at 58.0% of the total. Reporting peaked in 2019 at $41,338 and has fallen 92.5% since, to $3,113 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 883 payments — averaging $104.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$54K
- Amarin Pharma, Inc.$8K
- Medtronic$7K
- Abbott$6K
- Biotronik Inc.$3K
- Bard Peripheral Vascular, Inc.$2K
- plus $13K from 45 others
Across 25 payments — averaging $6447.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$161K
What the payments were for
- Consulting fees$6501%
- Speaking & faculty fees$55,09560%
- Travel & lodging$4,2615%
- Food & beverage$32,12935%
- Education$2240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$52,353
- Vascepa$7,896
- Confirm Rx$2,401
- VenaSeal$2,258
- COREVALVE EVOLUT R$1,822
- Venclose Maven Catheter$865
- OPTIMIZER$850
- EVRSF$728
- AVEIR$717
- WATCHMAN Access System$618
- Quadra Assura CRT Defibrillator$504
- BioMonitor$496
- CoreValve Evolut$458
- IN.PACT Admiral$366
- DXI 800$350
- JOT DX$346
- Quartet CRT Lead$317
- ClosureFast$255
- LEQVIO$250
- Solia$232
How this compares
$92,359 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 337 | $382,860 |
| VyndamaxTafamidis | 14 | $308,616 |
| EntrestoSacubitril/Valsartan | 191 | $258,435 |
| EliquisApixaban | 112 | $134,489 |
| BrilintaTicagrelor | 86 | $77,043 |
| OzempicSemaglutide | 45 | $63,806 |
| FarxigaDapagliflozin Propanediol | 48 | $58,134 |
| MounjaroTirzepatide | 40 | $50,002 |
| VascepaIcosapent Ethyl | 50 | $42,805 |
| NexlizetBempedoic Acid/Ezetimibe | 56 | $41,242 |
| JardianceEmpagliflozin | 31 | $36,413 |
| MultaqDronedarone Hcl | 21 | $36,312 |
| Repatha SyringeEvolocumab | 18 | $26,212 |
| Ranolazine ErRanolazine | 154 | $24,425 |
| JanuviaSitagliptin Phosphate | 14 | $18,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $129 | $443,105126 claims |
| Johnson & JohnsonXarelto | $53,561 | $382,860337 claims |
| NovartisEntresto | $909 | $258,435191 claims |
| AstraZenecaBrilinta, Farxiga | $286 | $135,177134 claims |
| Novo NordiskOzempic | $342 | $63,80645 claims |
| Esperion Therapeutics, Inc.Nexlizet | $593 | $41,24256 claims |
| Boehringer IngelheimJardiance | $458 | $36,41331 claims |
| Sanofi-aventis U.S. LLCMultaq | $433 | $36,31221 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $57 | $24,15148 claims |
| MerckJanuvia | $509 | $18,64814 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $385 | $13,79814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Humble
- Khaled KhalafHumble$185K
- Ricky GanimHumble$144K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.